Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon ...

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors ...

Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

Pfizer Inc. is offering about 662 million shares in Haleon Plc, representing its remaining stake in the maker of Sensodyne ...

Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.

Pfizer reportedly offered about 618 million shares through a placement with investors, according to a Wednesday statement.

Bengaluru: Pfizer will divest its remaining stake in Haleon, marking its complete exit from the British consumer healthcare ...

Haleon has agreed to an off-market purchase of 44,155,844 ordinary shares of £0.01 each from Pfizer. The off-market purchase is being made in conjunction with, and subject to the completion of an ...

Pfizer has fully exited its investment in UK-listed pharma group Haleon, selling off its remaining 7.3% stake for £2.5bn.

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.